- The report tracks the recent IPO market performance, focusing on the net gains from new stock listings across the Sci-Tech Innovation Board, ChiNext, and Main Board, assuming all stocks are successfully subscribed and sold at the market average price on the first trading day, excluding lock-up restrictions[1][11][39] - The cumulative IPO net gains for A-class accounts with a scale of 2 billion reached 2.44%, while B-class accounts of the same scale achieved 2.19% as of October 24, 2025[11][39] - For larger accounts with a scale of 10 billion, the IPO net gains were significantly lower, with A-class accounts at 0.77% and B-class accounts at 0.70%[11][39] - The average first-day price increase for Sci-Tech Innovation Board stocks was 218.45%, while ChiNext stocks saw an average increase of 244.28%[1][16] - The report provides detailed calculations for theoretical IPO gains, using formulas such as: $ Full subscription quantity = Maximum subscription limit × Average offline subscription rate $ $ Full subscription gains = (First-day average price - IPO price) × Full subscription quantity $[35][39] - The highest full subscription gains among recent IPOs were achieved by United Power, Jindal Zhixin, and C Marco, with gains of 50.81, 12.58, and 11.03 million yuan respectively[35][38] - The report also includes monthly tracking of IPO gains for A-class accounts across different scales, showing a cumulative gain rate of 6.17% for 2 billion accounts since 2024, and 2.44% for 2025 alone[39][41] - Similar tracking for B-class accounts reveals a cumulative gain rate of 5.11% for 2 billion accounts since 2024, and 2.19% for 2025 alone[47][45] - The report highlights the IPO subscription process, including strategic placement, offline inquiry, and online pricing methods, with detailed statistics on subscription rates, oversubscription multiples, and effective subscription ratios for recent IPOs like Xi'an Yicai and Bibet[24][25]

Core Points - Three companies, Bibit (688759.SH), Heyuan Bio (688765.SH), and Xi'an Yicai (688783.SH), are set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, marking the first batch of new listings since the launch of the Sci-Tech Growth Tier [1] - As of now, a total of 7.58 million investor accounts have opened trading permissions for the Sci-Tech Growth Tier, representing 126% of the active accounts among existing investors [1] - Following the release of the "1+6" policy reform for the Sci-Tech Board in June, 26 new companies have been accepted for listing, with 8 of them being unprofitable [1] - The first IPO application under the fifth set of listing standards, submitted by professional institutional investor Tianomaibo, was accepted on July 31 [1] - On September 26, the second IPO project under the restarted fifth set of listing standards, Anshi Bio, was accepted [1] - Companies such as Beixin Life, unprofitable company Moer Thread, and Angrui Micro have submitted registration on July 25, September 26, and October 15, respectively, under the fifth set of standards [1] - Unprofitable company Muxi Co. passed the listing committee review on October 24 [1]

Group 1: New Stock Performance - Two new stocks were listed last week (October 20-24), with an average first-day price increase of 263.20%[2] - Both new stocks had first-day gains exceeding 100%, specifically Chao Ying Electronics at 397.60% and Marco Polo at 128.80%[2][4] - The total fundraising amount for new stocks last week increased by 1.591 billion yuan compared to the previous week[3] Group 2: Weekly and Monthly Trends - The number of new stocks listed remained unchanged at 2 for the week of October 20-24, with no first-day price drops recorded[3] - For the week of October 13-17, the average first-day price increase was 325.18%, with two stocks showing gains over 100%[4] - Monthly data shows that from October 1 to October 24, 5 new stocks were listed, raising 3.653 billion yuan, with an average first-day increase of 305.31%[10]

Group 1 - The new stock sector experienced a significant rebound last week, with an average increase of 4.9% since the beginning of 2024, and approximately 90.8% of new stocks achieving positive returns [1][13][30] - The short-term sentiment in the new stock market is expected to stabilize after a period of volatility, but the upcoming quarterly earnings reports may introduce performance disturbances [2][13] - The focus remains on sectors with stable earnings expectations, particularly in new energy, new consumption, and non-ferrous metals, while also tracking long-term investment themes such as robotics, AI, and innovative pharmaceuticals [3][13] Group 2 - Last week, two new stocks were listed, with an average first-day increase of 263%, indicating high trading enthusiasm despite some differentiation in performance [5][27] - The average first-day closing price-to-earnings ratio for new stocks in October has significantly increased to 106.4X, compared to 54.5X in the previous month, suggesting a rising trend in new stock pricing [18][20] - The upcoming week will see the listing of several new stocks, including He Yuan Biological and Xi'an Yicai, with an average issuance price-to-earnings ratio of 17.8X for new stocks expected to be listed [4][35][38]

Core Insights - He Yuan Bio (688765) is set to debut on the Sci-Tech Innovation Board, becoming the first incremental enterprise in the Sci-Tech Growth Layer [1] - The Sci-Tech Growth Layer currently includes 13 innovative pharmaceutical companies with a total market capitalization of nearly 500 billion yuan, having facilitated the approval of 25 new drugs since their listing [1] Group 1: Institutional Reforms and Investment Trends - The reintroduction of the fifth set of listing standards on the Sci-Tech Board has allowed unprofitable companies to go public, significantly aiding innovative pharmaceutical firms in overcoming funding bottlenecks and accelerating drug development [2] - Since 2019, the cumulative financing scale of China's innovative drug industry in both primary and secondary markets has exceeded 1 trillion yuan, leading to a surge in research and development activities [2] - The establishment of the Sci-Tech Growth Layer in June aims to enhance the adaptability and inclusiveness of the Sci-Tech Board, supporting the development of new productive forces and technological innovation [2] Group 2: R&D and Commercialization Acceleration - High R&D investment is a primary reason for the current unprofitability of companies in the Sci-Tech Growth Layer, but it is also a key driver for future innovation [3] - In 2024, the total revenue of these innovative pharmaceutical companies is projected to reach 31.9 billion yuan, with a year-on-year growth rate of 54.39%, significantly outpacing the sector's average [3] - These companies have successfully launched 20 new drugs classified as "global new" and achieved "breakthrough therapy" designation for 10 innovative drugs across 17 indications [3] Group 3: Leading Companies and Market Performance - BeiGene, a leading unprofitable innovative drug company, has achieved a "qualitative leap" through a combination of advanced technology and commercialization strategies, with R&D investment reaching 14.1 billion yuan in 2024 [4] - BeiGene's core product, Zebrutinib, has become the first domestic innovative drug to exceed 1 billion dollars in sales, with 1.3 billion dollars in half-year sales revenue in the first half of this year, reflecting over 56% year-on-year growth [4] - The company anticipates revenues exceeding 35 billion yuan in 2025, with operating profits turning positive, entering a virtuous cycle of "R&D breakthroughs—product scaling—profit realization" [4] Group 4: International Collaborations and Market Recognition - Several companies in the Sci-Tech Growth Layer have actively pursued international transactions this year, with potential total transaction amounts nearing 5 billion dollars, indicating global market recognition of their innovative capabilities [5] - For instance, Maiwei Bio has entered into a licensing agreement with Calico, a biotech company founded by Alphabet Inc., with a potential transaction value of 596 million dollars [5] - Another example includes Nuo Cheng Jian Hua, which announced a licensing agreement with Nasdaq-listed Zenas BioPharma, expecting an upfront payment of 100 million dollars and potential total transaction value exceeding 2 billion dollars [5]

Group 1 - The core point of the article is that Chutian Technology is collaborating with Heyuan Biotechnology to provide solutions for the large-scale production of a globally innovative "rice-derived" product [2] - Chutian Technology confirmed on the investor interaction platform that Heyuan Biotechnology is one of its clients, and they are assisting in the establishment of the world's first plant-derived recombinant human albumin injection production line [2] - Chutian Technology's subsidiary, Chutian Yuanchuang, is supplying several sets of fully automated chromatography columns and associated online liquid chromatography systems, as well as multiple ultrafiltration systems for the project [2]

股票简称：禾元生物 股票代码：688765 武汉禾元生物科技股份有限公司 Wuhan Healthgen Biotechnology Corp. （武汉东湖新技术开发区神墩五路 268 号） 首次公开发行股票 科创板上市公告书 保荐人（联席主承销商） 中国（上海）自由贸易试验区商城路 618 号 联席主承销商 北京市朝阳区安立路 66 号 4 号楼 二〇二五年十月二十四日 武汉禾元生物科技股份有限公司 上市公告书 特别提示 武汉禾元生物科技股份有限公司（以下简称"禾元生物"、"发行人"、"公 司"、"本公司"）股票将于 2025 年 10 月 28 日在上海证券交易所科创板上市。 根据《上海证券交易所科创板上市公司自律监管指引第 5 号——科创成长 层》，上市时未盈利的科创板公司，自上市之日起纳入科创成长层。截至本公告 披露日，禾元生物尚未盈利，自上市之日起将纳入科创成长层。 普通投资者参与科创成长层股票或者存托凭证交易的，应当符合科创板投资 者适当性管理的要求，并按照上海证券交易所有关规定，在首次参与交易前以纸 面或者电子形式签署《科创成长层风险揭示书》，由证券公司充分告知相关风险。 本公司提醒投资者应充分 ...

武汉禾元生物科技股份有限公司 首次公开发行股票科创板 上市公告书提示性公告 保荐人（联席主承销商）：国泰海通证券股份有限公司 联席主承销商：中信建投证券股份有限公司 （一）股票简称：禾元生物 （二）扩位简称：武汉禾元生物 （三）股票代码：688765 （四）首次公开发行后总股本：357,500,000 股 二、风险提示 根据《上海证券交易所科创板上市公司自律监管指引第 5 号——科创成长 层》，上市时未盈利的科创板公司，自上市之日起纳入科创成长层。截至本公告 披露日，禾元生物尚未盈利，自上市之日起将纳入科创成长层。 普通投资者参与科创成长层股票或者存托凭证交易的，应当符合科创板投资 者适当性管理的要求，并按照上海证券交易所有关规定，在首次参与交易前以纸 面或者电子形式签署《科创成长层风险揭示书》，由证券公司充分告知相关风险。 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市初 期的投资风险，提醒投资者充分了解交易风险、理性参与新股交易，具体如下： 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海 ...

武汉禾元生物科技股份有限公司 章 程 （草案） 湖北 武汉 二零二五年七月 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | 第一节 | 股份发行 5 | | 第二节 | 股份增减和回购 7 | | 第三节 | 股份转让 8 | | 第四章 | 股东和股东会 9 | | 第一节 | 股东 9 | | 第二节 | 控股股东和实际控制人 11 | | 第三节 | 股东会的一般规定 12 | | 第四节 | 股东会的召集 14 | | 第五节 | 股东会的提案与通知 16 | | 第六节 | 股东会的召开 17 | | 第七节 | 股东会的表决和决议 19 | | 第五章 | 董事和董事会 24 | | 第一节 | 董事的一般规定 24 | | 第二节 | 董事会 27 | | 第三节 | 独立董事 32 | | 第四节 | 董事会专门委员会 35 | | 第六章 | 高级管理人员 36 | | 第七章 | 财务会计制度、利润分配和审计 38 | | 第一节 | 财务会计制度 38 | | 第二节 | 内部审计 42 | ...

武汉禾元生物科技股份有限公司 首次公开发行股票并在科创板上市 招股说明书提示性公告 保荐人（联席主承销商）：国泰海通证券股份有限公司 联席主承销商：中信建投证券股份有限公司 扫描二维码查阅公告全文 武汉禾元生物科技股份有限公司（以下简称"禾元生物"、"发行人"或 "公司"）首次公开发行股票并在科创板上市的申请已经上海证券交易所（以下 简称"上交所"）上市审核委员会审议通过，并已经中国证券监督管理委员会（以 下简称"中国证监会"）证监许可〔2025〕1468 号文同意注册。《武汉禾元生 物科技股份有限公司首次公开发行股票并在科创板上市招股说明书》在上海证券 交易所网站（http://www.sse.com.cn/）和符合中国证监会规定条件网站（中证网， 网址 www.cs.com.cn；中国证券网，网址 www.cnstock.com；证券时报网，网址 www.stcn.com；证券日报网，网址 www.zqrb.cn）披露，并置备于发行人、本次 发行保荐人（联席主承销商）国泰海通证券股份有限公司和联席主承销商中信建 投证券股份有限公司的住所，供公众查阅。 | | 本次发行基本情况 | | | | --- | ...